Combination therapies using anti-pseudomonas PSL and PCRV binding molecules

Patent metadata

Field	Value
Publication number	US-12428473-B2
Application number	US-202117454837-A
Country	US
Kind code	B2
Filing date	Nov 15, 2021
Priority date	Nov 7, 2011
Publication date	Sep 30, 2025
Grant date	Sep 30, 2025

Abstract

This disclosure relates to combination therapies comprising anti- Pseudomonas Psl and PcrV binding molecules and related compositions, for use in prevention and treatment of Pseudomonas infection.

First claim

What is claimed is:

1. An isolated antibody or antigen-binding fragment thereof that specifically binds to Pseudomonas PcrV, wherein the antibody or antigen-binding fragment thereof comprises:
(a) the heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO:218; the heavy chain CDR2 comprising amino acids 50-66 of SEQ ID NO:264; and the heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO:220; and
(b) the light chain CDR1 comprising the amino acid sequence of SEQ ID NO:221; the light chain CDR2 comprising the amino acid sequence of SEQ ID NO:222; and the light chain CDR3 comprising the amino acid sequence of SEQ ID NO:223.

2. The antibody or antigen-binding fragment thereof of claim 1 , comprising:
(a) the heavy chain variable region comprising amino acids 1-124 of SEQ ID NO:264; and
(b) the light chain variable region comprising amino acids 1-107 of SEQ ID NO:263.

3. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a recombinant monoclonal antibody or antigen-binding fragment thereof.

4. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a bispecific antibody or antigen-binding fragment thereof.

5. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is a recombinant monoclonal antibody or antigen-binding fragment thereof.

6. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof is a bispecific antibody or antigen-binding fragment thereof.

7. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a full-length antibody.

8. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is an antigen-binding fragment.

9. The antibody or antigen-binding fragment thereof of claim 8 , wherein the antigen-binding fragment is selected from the group consisting of: Fab fragment, Fab′ fragment, F(ab)2 fragment, and scFv fragment.

10. The antibody or antigen-binding fragment thereof of claim 4 , wherein the antibody or antigen-binding fragment thereof is an IgG antibody.

11. The antibody or antigen-binding fragment thereof of claim 10 , wherein the antibody or antigen-binding fragment thereof is an IgG1 antibody.

12. The antibody or antigen-binding fragment thereof of claim 6 , wherein the antibody or antigen-binding fragment thereof is an IgG antibody.

13. The antibody or antigen-binding fragment thereof of claim 12 , wherein the antibody or antigen-binding fragment thereof is an IgG1 antibody.

14. The antibody or antigen-binding fragment thereof of claim 4 , wherein the antibody or antigen-binding fragment thereof comprises a IgGκ constant region.

15. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof comprises a IgGλ constant region.

16. The antibody or antigen-binding fragment thereof of claim 6 , wherein the antibody or antigen-binding fragment thereof comprises a IgGκ constant region.

17. The antibody or antigen-binding fragment thereof of claim 2 , wherein the antibody or antigen-binding fragment thereof comprises a IgGλ constant region.

18. The antibody or antigen-binding fragment thereof of claim 1 , wherein the antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.

19. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1 , and a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 2 , and a pharmaceutically acceptable carrier.

Assignees

• Medimmune Ltd

Inventors

• Digiandomenico Antonio
• Warrener Paul
• Stover Charles
• Sellman Bret
• Minter Ralph
• Guillard Sandrine
• Rust Steven
• Tomich Mladen
• Venkatraman Vignesh
• Varkey Reena
• Peng Li
• Damschroder Melissa
• Chowdhury Partha S
• Dimasi Nazzareno
• Fleming Ryan
• Bezabeh Binyam
• Gao Changshou
• Rainey Godfrey
• Gao Cuihua

Classifications

• C07K2317/565

  Complementarity determining region [CDR] · CPC title

• C07K2317/56

  variable (Fv) region, i.e. VH and/or VL · CPC title

• A61K2039/507

  Comprising a combination of two or more separate antibodies · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• A61P31/04

  Antibacterial agents · CPC title